exenatide 5 or 10 micrograms, solution for injection, prefilled pen (Byetta)
Following a full submission
exenatide (Byetta®) is accepted for restricted use within NHS Scotland for the treatment of type 2 diabetes mellitus in combination with metformin and/or sulphonylureas in patients who have not achieved adequate glycaemic control on maximally tolerated doses of these oral therapies.
It has shown non-inferiority to two insulin regimens with which it has been compared and has a beneficial effect on weight. It is restricted to use as an alternative to insulin in patients who have failed treatment on metformin and/or sulphonylureas and in whom insulin would be the next treatment option.
|Drug Name:||exenatide 5 or 10 micrograms, solution for injection, prefilled pen (Byetta)|
|SMC Drug ID:||376/07|
|Manufacturer:||Eli Lilly and Company Ltd|
|Indication:||Type 2 diabetes mellitus|
|Sub Category:||6.1 Drugs used in diabetes|
|Submission Type:||Full submission|
|Date Advice Published:||9 July 2007|